Literature DB >> 25865476

Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy.

Elliot B Tapper1, Z Gordon Jiang2, Vilas R Patwardhan2.   

Abstract

Hepatic encephalopathy (HE) is one of the most important complications of cirrhosis and portal hypertension. Although the etiology is incompletely understood, it has been linked to ammonia directly and indirectly. Our goal is to review for the clinician the mechanisms behind hyperammonemia and the pathogenesis of HE to explain the rationale for its therapy. We reviewed articles collected through a search of MEDLINE/PubMed, Cochrane Database of Systematic Reviews, and Google Scholar between October 1, 1948, and December 8, 2014, and by a manual search of citations within retrieved articles. Search terms included hepatic encephalopathy, ammonia hypothesis, brain and ammonia, liver failure and ammonia, acute-on-chronic liver failure and ammonia, cirrhosis and ammonia, portosytemic shunt, ammonia and lactulose, rifaximin, zinc, and nutrition. Ammonia homeostatsis is a multiorgan process involving the liver, brain, kidneys, and muscle as well as the gastrointestinal tract. Indeed, hyperammonemia may be the first clue to poor functional reserves, malnutrition, and impending multiorgan dysfunction. Furthermore, the neuropathology of ammonia is critically linked to states of systemic inflammation and endotoxemia. Given the complex interplay among ammonia, inflammation, and other factors, ammonia levels have questionable utility in the staging of HE. The use of nonabsorbable disaccharides, antibiotics, and probiotics reduces gut ammoniagenesis and, in the case of antibiotics and probiotics, systemic inflammation. Nutritional support preserves urea cycle function and prevents wasting of skeletal muscle, a significant site of ammonia metabolism. Correction of hypokalemia, hypovolemia, and acidosis further assists in the reduction of ammonia production in the kidney. Finally, early and aggressive treatment of infection, avoidance of sedatives, and modification of portosystemic shunts are also helpful in reducing the neurocognitive effects of hyperammonemia. Refining the ammonia hypothesis to account for these other factors instructs a solid foundation for the effective treatment and prevention of hepatic encephalopathy.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25865476     DOI: 10.1016/j.mayocp.2015.03.003

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  40 in total

Review 1.  Ammonia Transporters and Their Role in Acid-Base Balance.

Authors:  I David Weiner; Jill W Verlander
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

2.  Lower values of handgrip strength and adductor pollicis muscle thickness are associated with hepatic encephalopathy manifestations in cirrhotic patients.

Authors:  L Augusti; L C Franzoni; L A A Santos; T B Lima; M V Ietsugu; K H Koga; S M Moriguchi; L E Betting; C A Caramori; G F Silva; F G Romeiro
Journal:  Metab Brain Dis       Date:  2016-04-30       Impact factor: 3.584

3.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

Review 4.  The Role of RRT in Hyperammonemic Patients.

Authors:  Shruti Gupta; Andrew Z Fenves; Robert Hootkins
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

5.  A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.

Authors:  Elliot B Tapper; Daniel Finkelstein; Murray A Mittleman; Gail Piatkowski; Matthew Chang; Michelle Lai
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-25       Impact factor: 11.382

6.  Gap Junction Intercellular Communication Mediates Ammonia-Induced Neurotoxicity.

Authors:  Larissa Daniele Bobermin; Bernardo Assein Arús; Marina Concli Leite; Diogo Onofre Souza; Carlos-Alberto Gonçalves; André Quincozes-Santos
Journal:  Neurotox Res       Date:  2015-12-08       Impact factor: 3.911

7.  Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis.

Authors:  Andrew M Moon; Yue Jiang; Shari S Rogal; Elliot B Tapper; Sarah R Lieber; A Sidney Barritt
Journal:  Aliment Pharmacol Ther       Date:  2020-01-21       Impact factor: 8.171

8.  Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.

Authors:  Elliot B Tapper; Neehar D Parikh; Pamela K Green; Kristin Berry; Akbar K Waljee; Andrew M Moon; George N Ioannou
Journal:  Clin Gastroenterol Hepatol       Date:  2019-10-04       Impact factor: 11.382

9.  Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index.

Authors:  Elliot B Tapper; Monica Konerman; Susan Murphy; Christopher J Sonnenday
Journal:  Am J Transplant       Date:  2018-08-13       Impact factor: 8.086

Review 10.  The Current Hepatic Encephalopathy Pipeline.

Authors:  Alexander J Ryu; Robert S Rahimi; Michael D Leise
Journal:  J Clin Exp Hepatol       Date:  2020-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.